Radiopharmaceutical · Cytotoxic, directed at prostate-specific membrane antigen (PSMA) (FOLH1) · developed by Novartis Pharmaceuticals
Lu-PSMA-617 is a radiolabeled ligand, [177Lu]Lu-PSMA-617, delivered intravenously as an infusion. It is designed to bind prostate-specific membrane antigen, a tumor antigen, and is being studied in metastatic neuroendocrine prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06379217 | Phase 1 | Metastatic Neuroendocrine Prostate Cancer | Terminated | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Neuroendocrine Prostate Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →